A detailed history of Jane Street Group, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 136,281 shares of ALNY stock, worth $32.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
136,281
Previous 139,497 2.31%
Holding current value
$32.1 Million
Previous $33.9 Million 10.59%
% of portfolio
0.01%
Previous 0.04%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$233.81 - $287.01 $751,932 - $923,024
-3,216 Reduced 2.31%
136,281 $37.5 Million
Q2 2024

Aug 14, 2024

SELL
$143.31 - $247.0 $3.5 Million - $6.04 Million
-24,441 Reduced 14.91%
139,497 $33.9 Million
Q1 2024

May 15, 2024

BUY
$146.51 - $198.2 $9.75 Million - $13.2 Million
66,575 Added 68.38%
163,938 $24.5 Million
Q4 2023

Feb 14, 2024

BUY
$151.41 - $196.57 $6.41 Million - $8.32 Million
42,327 Added 76.91%
97,363 $18.6 Million
Q3 2023

Nov 14, 2023

BUY
$170.77 - $211.65 $3.14 Million - $3.89 Million
18,394 Added 50.2%
55,036 $9.75 Million
Q2 2023

Aug 14, 2023

SELL
$185.01 - $212.05 $6.7 Million - $7.68 Million
-36,227 Reduced 49.72%
36,642 $6.96 Million
Q1 2023

May 15, 2023

SELL
$182.66 - $235.53 $8.42 Million - $10.9 Million
-46,107 Reduced 38.75%
72,869 $14.6 Million
Q4 2022

Feb 14, 2023

SELL
$185.53 - $241.31 $28.6 Million - $37.2 Million
-154,013 Reduced 56.42%
118,976 $28.3 Million
Q3 2022

Nov 14, 2022

BUY
$138.54 - $232.0 $19.8 Million - $33.2 Million
143,137 Added 110.23%
272,989 $54.6 Million
Q2 2022

Aug 16, 2022

BUY
$120.42 - $169.29 $7.5 Million - $10.5 Million
62,289 Added 92.19%
129,852 $18.9 Million
Q1 2022

May 17, 2022

SELL
$127.18 - $173.91 $6.15 Million - $8.42 Million
-48,394 Reduced 41.73%
67,563 $11 Million
Q4 2021

Feb 15, 2022

BUY
$159.56 - $209.29 $16 Million - $21 Million
100,355 Added 643.22%
115,957 $19.7 Million
Q3 2021

Nov 16, 2021

SELL
$169.75 - $207.73 $7.52 Million - $9.2 Million
-44,299 Reduced 73.95%
15,602 $2.95 Million
Q2 2021

Aug 16, 2021

BUY
$128.63 - $176.89 $5.42 Million - $7.45 Million
42,101 Added 236.52%
59,901 $10.2 Million
Q1 2021

May 18, 2021

BUY
$126.83 - $175.69 $1.38 Million - $1.92 Million
10,918 Added 158.65%
17,800 $2.51 Million
Q4 2020

Feb 17, 2021

SELL
$122.97 - $147.0 $918,462 - $1.1 Million
-7,469 Reduced 52.05%
6,882 $895,000
Q3 2020

Nov 17, 2020

SELL
$121.19 - $165.49 $7.93 Million - $10.8 Million
-65,446 Reduced 82.02%
14,351 $2.09 Million
Q2 2020

Aug 17, 2020

BUY
$104.21 - $156.44 $7.62 Million - $11.4 Million
73,111 Added 1093.49%
79,797 $11.8 Million
Q1 2020

May 15, 2020

SELL
$93.12 - $133.99 $494,094 - $710,950
-5,306 Reduced 44.25%
6,686 $728,000
Q3 2019

Nov 14, 2019

BUY
$70.9 - $87.82 $15,030 - $18,617
212 Added 1.8%
11,992 $965,000
Q2 2019

Aug 15, 2019

SELL
$65.86 - $92.79 $928,757 - $1.31 Million
-14,102 Reduced 54.49%
11,780 $855,000
Q1 2019

May 16, 2019

BUY
$72.76 - $93.45 $811,783 - $1.04 Million
11,157 Added 75.77%
25,882 $2.42 Million
Q4 2018

Feb 15, 2019

SELL
$62.67 - $88.33 $2.93 Million - $4.13 Million
-46,807 Reduced 76.07%
14,725 $1.07 Million
Q3 2018

Nov 14, 2018

BUY
$87.52 - $122.67 $5.39 Million - $7.55 Million
61,532 New
61,532 $5.39 Million
Q2 2018

Aug 15, 2018

SELL
$88.31 - $107.8 $815,719 - $995,748
-9,237 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$115.92 - $148.54 $694,013 - $889,308
5,987 Added 184.22%
9,237 $1.1 Million
Q4 2017

Feb 15, 2018

SELL
$114.49 - $139.98 $620,192 - $758,271
-5,417 Reduced 62.5%
3,250 $413,000
Q3 2017

Nov 14, 2017

BUY
$72.53 - $118.27 $628,617 - $1.03 Million
8,667
8,667 $1.02 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.